Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 7:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Covid19 Immunology Clear all
Terminated Phase 1Phase 2 Interventional Results available

Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19

NCT04365101
View directory record Official record
Conditions
Coronavirus, Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2, Pneumonia, Pneumonia, Viral, Lung Diseases, Respiratory Tract Disease, Respiratory Tract Infections, Coronaviridae Infections, Nidovirales Infections, RNA Virus Infections, Virus Disease, Immunologic Disease, ARDS, Immunologic Factors, Physiological Effects of Drugs, Antiviral Agents, Anti-infective Agents, Analgesics, Antimetabolites, Antineoplastic
Interventions
CYNK-001
Biological
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Irvine, California • Morristown, New Jersey • Summit, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 26, 2026, 7:23 AM EDT
Completed No phase listed Observational

COVID-19 Associated Lymphopenia Pathogenesis Study in Blood

NCT04401436
View directory record Official record
Conditions
Coronavirus Disease 2019
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 26, 2026, 7:23 AM EDT
Terminated Not applicable Interventional Results available

ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals

NCT05655546
View directory record Official record
Conditions
Immunodeficiency, Immunosuppression, HIV Infections, Graft Versus Host Disease, Leukemia, Lymphoma, Cancer, Multiple Myeloma, Transplant, Age-Related Immunodeficiency
Interventions
Access to Cue Health COVID-19 Remote testing and treatment for COVID-19
Other
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
2,117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Sep 26, 2026, 7:23 AM EDT
Terminated No phase listed Observational

Understanding Immunology and Patient Outcomes of COVID-19 in Hospitalized Patients

NCT04892797
View directory record Official record
Conditions
Covid19
Interventions
Covid-19+ observational
Other
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Sep 26, 2026, 7:23 AM EDT
Completed No phase listed Observational

Immunophenotyping Assessment in a COVID-19 Cohort

NCT04378777
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19), SARS-CoV-2
Interventions
Biological sample collection, Data Collection: Clinical Care Assessments
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
1,227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
17
States / cities
Tucson, Arizona • Los Angeles, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Sep 26, 2026, 7:23 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

QuadraMune(TM) for Prevention of COVID-19

NCT04421391
View directory record Official record
Conditions
Covid19, Coronavirus, SARS-CoV 2
Interventions
QuadraMune(TM)
Dietary Supplement
Lead sponsor
Therapeutic Solutions International
Industry
Eligibility
18 Years to 120 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Oceanside, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2020 · Synced Sep 26, 2026, 7:23 AM EDT
Not listed No phase listed Observational

Immune Response Following COVID-19 Vaccination

NCT04736524
View directory record Official record
Conditions
IgM and IgG in Blood
Interventions
Rapid antibody test
Other
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Other
Eligibility
16 Years to 85 Years
Enrollment
500 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Sep 26, 2026, 7:23 AM EDT
Completed No phase listed Observational

The COVID-19 PUI Reality Check (CPRC) Study

NCT04474288
View directory record Official record
Conditions
Covid19 Immunology
Interventions
SARS-CoV-2 antibody testing
Diagnostic Test
Lead sponsor
Bassett Healthcare
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Cooperstown, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Sep 26, 2026, 7:23 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Prevention and Treatment of Patient Before, During, and After Covid-19 Infection

NCT05043324
View directory record Official record
Conditions
Covid19
Interventions
AntiCov-220, AntiCov-220 (placebo)
Drug
Lead sponsor
Nguyen Thi Trieu, MD
Individual
Eligibility
16 Years to 82 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 26, 2026, 7:23 AM EDT
Completed Phase 1 Interventional Results available

A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19

NCT04646044
View directory record Official record
Conditions
Covid-19, Coronavirus Disease 2019
Interventions
Bempegaldesleukin, Standard of Care, Placebo
Drug · Other
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Hialeah, Florida • Winter Park, Florida • Mesquite, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 26, 2026, 7:23 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

COVID-19 Vaccine Responses in PIDD Subjects

NCT05321407
View directory record Official record
Conditions
X-linked Agammaglobulinemia, XLA, Primary Immune Deficiency, CVID, Common Variable Immunodeficiency, Primary Antibody Deficiencies, Secondary Hypogammaglobulinemia
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
6 Months and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
3
States / cities
St. Petersburg, Florida • Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced Sep 26, 2026, 7:23 AM EDT
Terminated Phase 2 Interventional

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O )

NCT04426201
View directory record Official record
Conditions
COVID-19, Lymphocytopenia
Interventions
CYT107, Placebo
Drug
Lead sponsor
Revimmune
Industry
Eligibility
25 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Sep 26, 2026, 7:23 AM EDT
Terminated Phase 2 Interventional

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I )

NCT04442178
View directory record Official record
Conditions
COVID-19, Lymphocytopenia
Interventions
CYT107, Placebo
Drug
Lead sponsor
Revimmune
Industry
Eligibility
25 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Gainesville, Florida • St Louis, Missouri • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Sep 26, 2026, 7:23 AM EDT
Terminated No phase listed Observational

COVID Cohort Study

NCT04393155
View directory record Official record
Conditions
COVID-19, Acute Respiratory Failure
Interventions
COVID-19+ observational
Other
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Sep 26, 2026, 7:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

COVID-19 Vaccination and Outcomes in Individuals With and Without Immune Deficiencies and Dysregulations

NCT04852276
View directory record Official record
Conditions
Immunodeficiencies, Immune Dysregulations
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years and older
Enrollment
308 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Sep 26, 2026, 7:23 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents

NCT04523246
View directory record Official record
Conditions
Herpes Zoster, Allergy and Immunology, Corona Virus Infection
Interventions
SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted), Normal Saline
Biological · Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
65 Years to 100 Years
Enrollment
217 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Sep 26, 2026, 7:23 AM EDT
Completed No phase listed Observational

COVID-19 Pregnancy Related Immunological, Clinical and Epidemiological Factors and Perinatal Outcomes

NCT04659759
View directory record Official record
Conditions
Covid19
Interventions
COVID-19 exposure, COVID-19 vaccine
Other · Biological
Lead sponsor
Thomas Jefferson University
Other
Eligibility
Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Sep 26, 2026, 7:23 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)

NCT04480424
View directory record Official record
Conditions
COVID-19
Interventions
GAMUNEX-C, Standard Medical Treatment
Biological · Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
18
States / cities
Chandler, Arizona • Coronado, California • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Sep 26, 2026, 7:23 AM EDT
Active, not recruiting No phase listed Observational

Evaluation of Immunologic Response Following COVID-19 Vaccination in Children, Adolescents, and Young Adults With Cancer

NCT05228275
View directory record Official record
Conditions
COVID-19 Infection, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Survey Administration
Procedure · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
6 Months to 37 Years
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
72
States / cities
Birmingham, Alabama • Kingman, Arizona • Oakland, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 26, 2026, 7:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)

NCT05289037
View directory record Official record
Conditions
COVID-19
Interventions
AS03, BNT162b2, BNT162b2 (B.1.1.529), BNT162b2 (B.1.351), BNT162b2 bivalent (wildtype and Omicron BA.1), BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5), CoV2 preS dTM [B.1.351], CoV2 preS dTM/D614, CoV2 preS dTM/D614+B.1.351, mRNA-1273, mRNA-1273.351, mRNA-1273.529, mRNA-1273.617.2, Sodium Chloride, 0.9%
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
1,270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
22
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 26, 2026, 7:23 AM EDT
Completed Phase 2 Interventional Results available

Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine

NCT04025580
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Flucelvax, Fluvirin, Fluzone High Dose
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Sep 26, 2026, 7:23 AM EDT
Terminated Phase 2 Interventional

Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection

NCT04487444
View directory record Official record
Conditions
Covid19
Interventions
Thymalfasin
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Sep 26, 2026, 7:23 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Creating a Virtual Village for People Aging With HIV During COVID-19

NCT04747756
View directory record Official record
Conditions
Hiv, Depression in Old Age, Isolation, Social, Aging
Interventions
Virtual Village
Other
Lead sponsor
University of California, Riverside
Other
Eligibility
50 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Riverside, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Sep 26, 2026, 7:23 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

A Registry Study of COVID-19 Serologic and Virologic Testing to Accelerate Recovery and Transition

NCT04573634
View directory record Official record
Conditions
Covid19, SARS-CoV Infection
Interventions
Not listed
Lead sponsor
Jill M Kolesar
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Sep 26, 2026, 7:23 AM EDT